What we do Murae Organisor Ltd markets, trades, and distributes pharmaceuticals including antibiotics, analgesics, multivitamins, and APIs, with a portfolio of 125 products, trading under own and third-party brands. |
Founded in 2,012 |
Market share Operates in pharmaceutical trading with significant business growth reflected by revenue scaling from Rs. 3.2 Cr to Rs. 854 Cr in FY 2024-25. |
Problem solved Provides access to a wide range of pharmaceutical formulations and active ingredients, supporting healthcare needs across multiple therapeutic areas. |
Top clients or who we serve Supplies pharmaceutical formulations to healthcare providers and distributors; operates primarily B2B. |
Key management Mr. Nitinkumar Ashokkumar Tomar, Managing Director & Chairperson, among other experienced directors. |
Our journey and innovations Founded in 2012, shifted from pharmaceutical trading to agriculture trading segment recently; expanded equity via IPO and preferential allotments. |
Where we operate Primarily India; no explicit exports noted. |
Top products or what we offer Around 125 pharmaceutical products including antibiotics, antimalarials, analgesics and active pharmaceutical ingredients like Levofloxacin and Amoxicillin. |
Top brands Markets 24 proprietary pharmaceutical brands with outsourced manufacturing; key product categories include antibiotics and multivitamins. |
Raw materials needed Various active pharmaceutical ingredients such as Levofloxacin Hemihydrate, Albendazole IP, Amoxicillin Trihydrate. |
Raw materials supplier Third-party pharmaceutical ingredient manufacturers; unspecified names. |
Recurring vs cyclical contribution Revenue primarily from recurring pharmaceutical trading activities. |
Our industry position Emerging player with recent significant revenue growth; mainly a pharmaceutical distributor and trader. |
Financial highlights FY 2024-25 Revenue: Rs. 854.82 Cr; Net Profit: Rs. 7.52 Cr vs Rs. 3.20 Cr revenue previous year. |
Geographical revenue split - |
Order book - |
Whats driving growth Strong equity infusion, business model focused on direct trading, expanding product portfolio, and shifting business segments for growth. |
Our future plans Increasing authorized capital, equity shares split and bonus issue to enhance shareholder value; exploring new growth avenues. |
Our green promise - |
Our people and values Board actively evaluates performance; policies for ethical business and whistleblowing implemented; no major HR issues reported. |
Key challenges ahead Documentary and regulatory compliance improvements needed; managing unsecured loans and party confirmations for financial clarity. |
Interesting facts Shifted from pharmaceutical trading to agriculture trading, massive revenue growth in a year, substantial equity capital increase. |
Risks and strategy Managing loans and supplier confirmations strategically; adherence to evolving regulatory compliance; leveraging direct trade model. |
